VOR Overview

Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.

Wall Street analysts forecast VOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VOR is38.67 USD with a low forecast of 9.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Vor Biopharma Inc revenue for the last quarter amounts to -35.96M USD, increased 14.85

Vor Biopharma Inc. EPS for the last quarter amounts to -23115000.00 USD, decreased -4.23

Vor Biopharma Inc (VOR) has 76 emplpoyees as of April 20 2026.

Today VOR has the market capitalization of 810.38M USD.